On January 22, 2026 Abbott (NYSE: ABT) reported financial results for the fourth quarter ended Dec. 31, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales1.
Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent.
Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales2.
Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent.
Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.
In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market. Abbott continues to expect the transaction to close in the second quarter of 2026.
Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:
In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt PFA System, bringing Abbott’s first pulsed field ablation (PFA) offering to patients in the United States.
In January, Abbott announced the company obtained CE Mark for its TactiFlex Duo Ablation Catheter, Sensor Enabled, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.
"In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future," said Robert B. Ford, chairman and chief executive officer, Abbott. "We’re well positioned for accelerating growth in 2026."
FOURTH-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
4,383
806
967
—
2,605
International
7,076
1,134
1,490
1,382
3,070
Total reported
11,459
1,940
2,457
1,382
5,675
% Change vs. 4Q24
U.S.
0.9
(13.2)
(8.4)
n/a
10.7
International
6.7
(5.6)
1.8
9.0
13.7
Total reported
4.4
(8.9)
(2.5)
9.0
12.3
Impact of foreign exchange
1.4
0.2
1.1
2.0
1.9
Organic
3.0
(9.1)
(3.6)
7.0
10.4
Impact of COVID-19 testing sales 1
(0.8)
—
(3.4)
—
—
Organic (excluding COVID-19 tests)
3.8
(9.1)
(0.2)
7.0
10.4
Organic
U.S.
0.9
(13.2)
(8.4)
n/a
10.7
International
4.3
(5.9)
(0.2)
7.0
10.1
Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
17,126
3,606
3,535
—
9,968
International
27,202
4,845
5,402
5,536
11,419
Total reported
44,328
8,451
8,937
5,536
21,387
% Change vs. 12M24
U.S.
4.9
(2.3)
(7.7)
n/a
13.4
International
6.1
2.6
(2.0)
6.6
12.0
Total reported
5.7
0.4
(4.3)
6.6
12.6
Impact of foreign exchange
0.2
(0.7)
0.2
(0.8)
0.7
Impact of business exit*
—
(0.1)
—
—
—
Organic
5.5
1.2
(4.5)
7.4
11.9
Impact of COVID-19 testing sales 2
(1.2)
—
(4.9)
—
—
Organic (excluding COVID-19 tests)
6.7
1.2
0.4
7.4
11.9
Organic
U.S.
5.0
(1.9)
(7.7)
n/a
13.4
International
5.9
3.7
(2.3)
7.4
10.5
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.
Nutrition
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)
Total
Pediatric
Adult
U.S.
806
463
343
International
1,134
439
695
Total reported
1,940
902
1,038
% Change vs. 4Q24
U.S.
(13.2)
(17.7)
(6.3)
International
(5.6)
0.3
(8.9)
Total reported
(8.9)
(9.8)
(8.1)
Impact of foreign exchange
0.2
0.3
0.1
Organic
(9.1)
(10.1)
(8.2)
U.S.
(13.2)
(17.7)
(6.3)
International
(5.9)
(0.3)
(9.1)
Worldwide Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in the fourth quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and new strategic price actions targeted to increase volume growth in the future. In addition to these strategic price actions, Abbott expects to increase volume growth with the launch of several new products in 2026.
Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)
Total
Pediatric
Adult
U.S.
3,606
2,158
1,448
International
4,845
1,816
3,029
Total reported
8,451
3,974
4,477
% Change vs. 12M24
U.S.
(2.3)
(2.3)
(2.2)
International
2.6
0.1
4.1
Total reported
0.4
(1.2)
2.0
Impact of foreign exchange
(0.7)
(0.5)
(0.7)
Impact of business exit*
(0.1)
—
(0.3)
Organic
1.2
(0.7)
3.0
U.S.
(1.9)
(2.3)
(1.4)
International
3.7
1.3
5.1
*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.
Diagnostics
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
967
376
39
107
445
International
1,490
1,085
102
51
252
Total reported
2,457
1,461
141
158
697
% Change vs. 4Q24
U.S.
(8.4)
3.6
2.9
6.5
(19.7)
International
1.8
5.9
3.3
9.8
(14.1)
Total reported
(2.5)
5.3
3.2
7.5
(17.8)
Impact of foreign exchange
1.1
1.7
2.1
0.4
0.3
Organic
(3.6)
3.6
1.1
7.1
(18.1)
U.S.
(8.4)
3.6
2.9
6.5
(19.7)
International
(0.2)
3.6
0.4
8.3
(14.9)
Global Diagnostics sales decreased 2.5 percent on a reported basis, decreased 3.6 percent on an organic basis, and decreased 0.2 percent when excluding COVID-19 testing-related sales1.
COVID-19 testing-related sales were $89 million in the quarter, compared to $176 million in the fourth quarter of the prior year.
Global Core Laboratory Diagnostics sales increased 5.3 percent on a reported basis and increased 3.6 percent on an organic basis. Growth in other geographies was partially offset by challenging market conditions in China, including the impact of volume-based procurement programs.
Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
3,535
1,425
150
422
1,538
International
5,402
3,935
367
184
916
Total reported
8,937
5,360
517
606
2,454
% Change vs. 12M24
U.S.
(7.7)
7.0
0.4
3.4
(20.8)
International
(2.0)
0.8
(1.1)
2.5
(13.3)
Total reported
(4.3)
2.4
(0.7)
3.1
(18.1)
Impact of foreign exchange
0.2
0.3
0.5
—
(0.1)
Organic
(4.5)
2.1
(1.2)
3.1
(18.0)
U.S.
(7.7)
7.0
0.4
3.4
(20.8)
International
(2.3)
0.4
(1.8)
2.4
(13.1)
Established Pharmaceuticals
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
1,382
1,046
336
Total reported
1,382
1,046
336
% Change vs. 4Q24
U.S.
n/a
n/a
n/a
International
9.0
10.3
5.0
Total reported
9.0
10.3
5.0
Impact of foreign exchange
2.0
1.6
3.1
Organic
7.0
8.7
1.9
U.S.
n/a
n/a
n/a
International
7.0
8.7
1.9
Established Pharmaceuticals sales increased 9.0 percent on a reported basis and 7.0 percent on an organic basis in the fourth quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 10.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in India and several countries across Latin America and the Middle East.
Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
5,536
4,167
1,369
Total reported
5,536
4,167
1,369
% Change vs. 12M24
U.S.
n/a
n/a
n/a
International
6.6
8.0
2.5
Total reported
6.6
8.0
2.5
Impact of foreign exchange
(0.8)
(1.5)
1.1
Organic
7.4
9.5
1.4
U.S.
n/a
n/a
n/a
International
7.4
9.5
1.4
Medical Devices
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)
Total
Rhythm
Management
Electro-
physiology
Heart
Failure
Vascular
Structural
Heart
Neuro-
modulation
Diabetes
Care
U.S.
2,605
340
340
283
287
304
208
843
International
3,070
365
390
92
496
371
66
1,290
Total reported
5,675
705
730
375
783
675
274
2,133
% Change vs. 4Q24
U.S.
10.7
12.8
13.1
11.7
6.5
4.8
1.9
14.9
International
13.7
13.4
13.9
17.9
8.9
16.3
23.8
14.2
Total reported
12.3
13.1
13.5
13.2
8.0
10.8
6.5
14.5
Impact of foreign exchange
1.9
1.6
1.0
1.1
1.5
2.1
0.9
2.8
Organic
10.4
11.5
12.5
12.1
6.5
8.7
5.6
11.7
U.S.
10.7
12.8
13.1
11.7
6.5
4.8
1.9
14.9
International
10.1
10.2
11.9
13.4
6.6
12.3
19.6
9.6
Worldwide Medical Devices sales increased 12.3 percent on a reported basis and 10.4 percent on an organic basis in the fourth quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors were $2.0 billion and grew 15.0 percent on a reported basis and 12.2 percent on an organic basis.
Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)
Total
Rhythm
Management
Electro-
physiology
Heart
Failure
Vascular
Structural
Heart
Neuro-
modulation
Diabetes
Care
U.S.
9,968
1,334
1,283
1,107
1,118
1,172
773
3,181
International
11,419
1,315
1,481
341
1,877
1,351
237
4,817
Total reported
21,387
2,649
2,764
1,448
2,995
2,523
1,010
7,998
% Change vs. 12M24
U.S.
13.4
15.7
12.4
12.2
5.8
11.5
0.8
20.8
International
12.0
6.4
11.7
16.4
5.4
13.0
21.5
15.4
Total reported
12.6
10.9
12.0
13.2
5.6
12.3
5.0
17.5
Impact of foreign exchange
0.7
0.7
0.4
0.5
0.5
0.8
0.2
1.2
Organic
11.9
10.2
11.6
12.7
5.1
11.5
4.8
16.3
U.S.
13.4
15.7
12.4
12.2
5.8
11.5
0.8
20.8
International
10.5
5.0
10.9
14.3
4.7
11.5
20.5
13.5
(Press release, Abbott, JAN 22, 2026, View Source [SID1234662161])